
Pharmacists interact with patients more than any other member of the health care team, therefore it is vital they help address barriers and gaps in member care that impact plan performance.

Pharmacists interact with patients more than any other member of the health care team, therefore it is vital they help address barriers and gaps in member care that impact plan performance.

Pharmacists can play a direct role in addressing social disparities of health in low-income communities by building trust and providing expertise to patients.

Further integration with care teams and using data to demonstrate the value of pharmacists will be essential to maintaining the momentum created by the COVID-19 pandemic.

When looking at the COVID-19 variants, it is increasingly necessary to assess them in terms of the mutations embedded in the variants themselves.

During a session at the NACDS 2021 Annual Meeting, Scott Gottlieb, MD, former commissioner of the FDA from 2017 to 2019, provided an overview of where the country is heading in its response to the COVID-19 pandemic.

The efforts of pharmacists to keep their doors open during the pandemic, build COVID-19 testing sites, and prepare for and administer COVID-19 vaccinations took extraordinary investment and determination.

Cedric Richmond, senior advisor to President Biden and director of the White House Office of Public Engagement, thanked the NACDS and other health care providers for their hard work during a session at the 2021 NACDS Annual Meeting.

According to Michael Sneed, executive vice president of global corporate affairs and chief communication officer for Johnson & Johnson, the health care system has chronically left people of color behind, and the inequities seen throughout the COVID-19 pandemic are only the latest examples.

Clinicians should consider the impact on subsequent therapies, overall survival, and median time to definitive deterioration with CDK 4/6 inhibitors.

Open to all health care professionals, the PQA meeting is a top forum for learning best practices and emerging trends in medication services, pharmacist-provided care, and quality improvement initiatives.

Among somatic mutations, approximately 89% of patients with metastatic castration-resistant prostate cancer have a potentially actionable mutation.

Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.

Patient interactions became vastly different during the pandemic, with questions surrounding how to coordinate contact and how to best provide pharmacy services virtually, including counseling, fielding drug information questions, medication reconciliation, and providing home medication sheets to families

Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.

Pharmacokinetic differences in pediatric patients should be considered when administering direct oral anticoagulants, as should potential administration difficulties when pellets or oral solutions are not available.

Selection of any BTK inhibitors for mantle cell lymphoma should consider factors such as cardiovascular or bleeding risks, predisposition for gastrointestinal adverse effects, and potential medication nonadherence.

CLL is the most common leukemia in adult patients in the western world, with 21,040 estimated new cases in 2020.

For unresectable gastrointestinal stromal tumors, the introduction of imatinib revolutionized treatment.

Urothelial carcinoma is the sixth most common cancer diagnosis in the United States, with an estimated 81,400 new diagnoses in 2020 and 17,980 deaths.

Oral chemotherapies can be effective treatments for children with low-grade gliomas, although clinicians should consider available formulations and administration schedules.

Home infusion within the larger ambulatory infusion setting poses some specific advantages and disadvantages in relation to the other location options available.

In each trial, overall response rate and median progression-free survival in the novel treatment arm showed significant improvement over the sunitinib treatment arm in patients with renal cell carcinoma.

Lakesha M. Butler, PharmD, BCPS, diversity and inclusion coordinator and clinical professor at Southern Illinois University Edwardsville, discussed causes of health inequity and how pharmacists can prevent and mitigate them to improve patient outcomes.

A drug recycling program can help increase patient access and minimize waste of expensive oral cancer medications.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.

A session at the Hematology/Oncology Pharmacy Association Virtual Annual Conference provided an overview of how treatment options are changing with potential new therapies in development for patients with non-small cell lung cancer.

A presentation at the Community Oncology Alliance 2021 Virtual Conference focused on the latest developments in gastrointestinal oncology and how the field of gastroesophageal cancer is responding to 3 major, practice-changing trials.

For the future of precision medicine, many health care providers hope to see a flood of new therapies for biomarker testing to be approved in the next few months.